Skip to Content
Learn more about MS

Dantrolene Pregnancy and Breastfeeding Warnings

Dantrolene is also known as: Dantrium, Dantrium Intravenous, Revonto, Ryanodex

Medically reviewed on January 30, 2017

Dantrolene Pregnancy Warnings

Dantrolene has been assigned to pregnancy category C by the FDA. Studies in animals have revealed evidence of embryotoxicity. There are no controlled data in human pregnancy. Dantrolene should only be given during pregnancy when benefit outweighs risk.

Dantrolene has been used in one uncontrolled study prophylactically prior to and after delivery in obstetric patients who were at risk for malignant hyperthermia. Relatively low doses of 100 mg/day were used 5 days prior to and 3 days after delivery. Although dantrolene crossed the placenta, no untoward effects were noted in the fetuses or neonates.

See references

Dantrolene Breastfeeding Warnings

There are no data on the excretion of dantrolene into human milk. The manufacturer recommends that dantrolene not be used in nursing mothers.

See references

References for pregnancy information

  1. "Product Information. Dantrium (dantrolene)." Procter and Gamble Pharmaceutic, Cincinnati, OH.
  2. Pennati A, Sacchetti E, Calzeroni A "Dantrolene in lethal catatonia." Am J Psychiatry 148 (1991): 268

References for breastfeeding information

  1. "Product Information. Dantrium (dantrolene)." Procter and Gamble Pharmaceutic, Cincinnati, OH.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide